With controlled room temperature (CRT) being one of the newer categories pharma handles in its supply chains, inefficiencies remain in how the industry manages the distribution of these products.
The global clinical trial supplies market is expected generate revenues of US$3.3 billion by 2025 on the back of a sharp rise in the number of complex clinical trial studies, according to a new report by consultancy Grand View Research.
Andrew Love assesses how to avoid the supply risk when working with CMOs on serialization. In this article, he reveals another six learnings covering everything from project design to catering for ongoing change.
Although some flaws remain in transporting Controlled Room Temperature (CRT) drugs via airfreight, providers in the space are taking strides to make the air more viable for medical cargo
This webinar addresses the challenges and issues faced by cold chain stakeholders when they have to select the right equipment to monitor their shipments.
With the evolution of technology and multiple IT systems in logistics, it is proving demanding for shippers to determine how to connect various sources of data and information to unlock meaningful findings
According the Alan Kennedy Founder, Team-Up Global, its time for pharma to step up. Only by adopting a more collaborative approach to pharma logistics can it extract the benefits that are being routinely achieved by more progressive sectors
This is the second article in a series looking at how to avoid the supply risk when working with CMOs on serialization. In this article Andrew Love discusses another six learnings covering everything from resource-planning to clarifying your RACI.
Pharma Logistics IQ presents a list of trade groups supporting the stakeholders tasked with transporting and distributing medicines.
The FDA has published draft guidance proposing a 12 month grace period on the enforcement of November’s DSCSA requirements. Even still the industry should continue serialization projects to secure supply chains ahead of 2017's deadline.